RTGN — RetinalGenix Technologies Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 0.806 | 2.08 | 2.18 | 3.91 | 2.09 |
Operating Profit | -0.806 | -2.08 | -2.18 | -3.91 | -2.09 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -0.806 | -2.08 | -2.18 | -3.91 | -2.09 |
Net Income After Taxes | -0.806 | -2.08 | -2.18 | -3.91 | -2.09 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.806 | -2.08 | -2.18 | -3.91 | -2.09 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.806 | -2.08 | -2.18 | -3.91 | -2.09 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.056 | -0.145 | -0.153 | -0.227 | -0.12 |
Dividends per Share |